R. Fink

Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting

C. Slingluff, W. Grosh, G. Petroni, 2007, Clinical Cancer Research.

Multipeptide Vaccine for Melanoma ISA-51 Adjuvant and Administered as Part of Colony-Stimulating Factor and Montanide with Granulocyte-Macrophage Peptides Are Immunogenic When Combined MAGE-A 1-, MAGE-A 10-, and gp 100-Derived

E. Bissonette, C. Slingluff, W. Grosh, 2005 .

Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.

C. Slingluff, W. Grosh, W. Olson, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MAGE-A1-, MAGE-A10-, and gp100-Derived Peptides Are Immunogenic When Combined with Granulocyte-Macrophage Colony-Stimulating Factor and Montanide ISA-51 Adjuvant and Administered as Part of a Multipeptide Vaccine for Melanoma1

Gina R Petroni, E. Bissonette, C. Slingluff, 2005, The Journal of Immunology.

Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function

C. Slingluff, W. Olson, K. Chianese-Bullock, 2011, Journal of Translational Medicine.

Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.

C. Slingluff, W. Grosh, W. Olson, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.